Comparative Pharmacology
Head-to-head clinical analysis: SOLIRIS versus SYNAGIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOLIRIS versus SYNAGIS.
SOLIRIS vs SYNAGIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.
Palivizumab is a humanized monoclonal antibody that binds to the A antigenic site of the fusion (F) protein of respiratory syncytial virus (RSV), inhibiting viral entry into host cells by preventing fusion of the viral envelope with the host cell membrane.
600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (aHUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.
15 mg/kg intramuscular once monthly during RSV season. Maximum dose: 300 mg (2 mL) per injection.
None Documented
None Documented
Terminal elimination half-life: approximately 11.3 ± 3.4 days (range 8–18 days) following biweekly dosing. This supports a dosing interval of every 2 weeks for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
18-27 days (terminal half-life in pediatric patients, mean ~21 days). Allows monthly dosing during RSV season.
Eculizumab is not metabolized by cytochrome P450 enzymes; it is degraded via general protein catabolism. Clearance is primarily through the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). No biliary or fecal excretion data are available in humans.
Renal: minimal intact IgG recovered in urine; likely catabolized to peptides/amino acids. Fecal/biliary: not significantly eliminated. Main route: proteolytic catabolism.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody